Market closed
MediWound Ltd./$MDWD
MediWound shares are trading higher after the company announced Phase II data showing EscharEx®'s superiority over collagenase in venous leg ulcers.
6 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Ticker
$MDWD
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Yavne, Israel
Employees
111
ISIN
IL0011316309
Website
MediWound Ltd. Metrics
BasicAdvanced
$202M
-
-$3.03
0.82
-
Price and volume
Market cap
$202M
Beta
0.82
52-week high
$19.68
52-week low
$14.14
Average daily volume
64K
Financial strength
Current ratio
1.965
Quick ratio
1.864
Long term debt to equity
20.906
Total debt to equity
22.248
Interest coverage (TTM)
-1.80%
Management effectiveness
Return on assets (TTM)
-17.33%
Return on equity (TTM)
-96.33%
Valuation
Price to revenue (TTM)
9.185
Price to book
6.46
Price to tangible book (TTM)
6.48
Price to free cash flow (TTM)
-9.336
Growth
Revenue change (TTM)
8.22%
Earnings per share change (TTM)
307.26%
3-year revenue growth (CAGR)
-5.24%
3-year earnings per share growth (CAGR)
-4.48%
MediWound Ltd. News
AllArticlesVideos
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
GlobeNewsWire·15 hours ago
MediWound to Report First Quarter 2025 Financial Results
GlobeNewsWire·1 week ago
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MediWound Ltd. stock?
MediWound Ltd. (MDWD) has a market cap of $202M as of May 14, 2025.
What is the P/E ratio for MediWound Ltd. stock?
The price to earnings (P/E) ratio for MediWound Ltd. (MDWD) stock is 0 as of May 14, 2025.
Does MediWound Ltd. stock pay dividends?
No, MediWound Ltd. (MDWD) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next MediWound Ltd. dividend payment date?
MediWound Ltd. (MDWD) stock does not pay dividends to its shareholders.
What is the beta indicator for MediWound Ltd.?
MediWound Ltd. (MDWD) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.